1411. Tecioplanin (TEI) vs Vancomycin (VAN) in Combination with Piperacillin -Tazobactam (TZP) or Meropenem (MER) as a Cause of Acute Kidney Injury (AKI)
Session: Poster Abstract Session: PK/PD Studies
Friday, October 5, 2018
Room: S Poster Hall
  • ID WEEK POSTER-MA 25.09.18-converted.pdf (299.2 kB)
  • <>Background:

     VAN has been shown to cause increased incidence of AKI when combined with TZP. The reason is unknown. TEI is a glycopeptide which may be less nephrotoxic. We compared both glycopeptides in combination with TZP or MER for causing AKI.


    A retrospective cohort study was performed between May 2015 and December 2017 in a large tertiary care setting. Evaluation of AKI was made by using RIFLE criteria. Patients ≥18 years were included if they had a baseline serum creatinine available and received one of the combinations tested for at least 48 h. Exclusion criteria were renal replacement therapy, pregnancy, <48 h antibiotic therapy and no follow up.


    Overall 456 patients were screened and 379 included in the study. After controlling for residual differences (age, Charlson comorbidity index score, presence of AKI, GFR value, presence of sepsis or septic shock, residing in intensive care unit at the time of antibiotic therapy and number of days of antibiotic therapy), AKI incidence was significantly higher in patients receiving TZP-VAN than those receiving TZP-TEI and also in patients receiving TZP-VAN than those with MER-VAN. No difference in AKI was detected between patients with MER-VAN and with MER-TEI (Table). Mortality at 7 and 30 days and resolution of AKI at discharge were similar in all groups.

    Açýklama: C:\Users\cdw\Desktop\Ekran Alýntýsý.PNG



    TZP causes increased nephrotoxicity when combined with VAN. Combination with TEI may offset this side effect. Additionally, the higher AKI incidence with TZP-VAN than MER-VAN may suggest a particular nephrotoxic synergy between TZP and VAN. Randomized controlled trials should confirm this observation.


    Abdullah Tarik Aslan, RESIDENT1, Tural Pashayev, RESIDENT1, Osman Dağ, DOCTOR2 and Murat Akova, PROF3, (1)Internal Medicine, HACETTEPE UNIVERSITY, ANKARA, Turkey, (2)Biostatistics, HACETTEPE UNIVERSITY, ANKARA, Turkey, (3)Infectious Diseases and Clinical Microbiology, HACETTEPE UNIVERSITY, ANKARA, Turkey


    A. T. Aslan, None

    T. Pashayev, None

    O. Dağ, None

    M. Akova, None

    See more of: PK/PD Studies
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.